TARGET I RCT (n¼227), TARGET I long stent cohort (n¼50), and TARGET II registry (n¼730) was prospectively collected and analyzed in 1007 patients with de novo native coronary lesions. All patients were exclusively treated with FIRE-HAWK stent and the follow-up visits are at 1-, 6-, 12-month, and annually up to 5 years. Results: 992 (98.5%) patients completed 2-year clinical follow-up. Between 1 and 2 years, 62% of patients discontinued DAPT and there were only 7 newly occurred TLF events including 3 cardiac death, 1 TV-MI and 3 iTLR (table) . Importantly, no definite/probable stent thrombosis (ST) was observed in this cohort 5 days after implantation of FIREHAWK stents. Lesion length >¼30mm was an independent predictor of TLF at 2 years (HR [95%CI]: 2.44 [1.32, 4.53], p< 0.01).
Background: In this randomized controlled study (RCT) we compare the clinical efficacy of the Orsiro Hybrid Drug Eluting Stent (Orsiro) with the Xience PrimeÔ Everolimus Eluting Stent (Xience) at 2 years in the complete study population as well as in the diabetic and small vessel subgroups, which are known to have a higher risk for cardiac complications. Methods: A total of N¼458 subjects (63.4AE10.0SD 36-80 yrs) were enrolled in the BIOFLOW-II study, registered at clinicaltrials.gov (NCT01356888). All subjects were stratified for diabetes and then randomly assigned (2:1) to receive the Orsiro or the Xience stent. Six patients were excluded from the intention to treat population. The diabetic subgroup accounted for 28.3% N¼128 (Orsiro N¼84, Xience N¼44) of all subjects. The small vessel cohort included all subjects with a reference vessel diameter 2.75mm, accounting for 57.3% N¼259 (Orsiro N¼168, Xience N¼91) of all subjects. Clinical follow up visits are performed at 1, 6, 12 months and annually for up to 5 years after the procedure. All angiographic images were analyzed by the core lab of R. Waksman, MD at MedStar Health Research Institute, Washington DC, USA. All clinical events were adjudicated by 3 independent cardiologists (MD:s). Results: All three study groups showed comparable populations in both randomization arms in terms of demographics, current risk factors, clinical history and lesion/ vessel characteristics. The clinical endpoint of Target Lesion Failure (TLF) for Orsiro vs Xience at 12 month in the three analyzed populations were: All patients -6.5% for the Orsiro vs 8.0% for the Xience (p 0.5832) Diabetic subgroup -6.0% for the Orsiro vs 4.5% for the Xience (p 0.7201) Small vessel subgroup -7.4% for the Orsiro vs 12.3% for the Xience (p 0.2065) No stent thrombosis (definitive, probable or possible) occurred through 12 months. The clinical 2-year follow up data is currently being analyzed. Results will be presented for the first time during the meeting. Conclusions: In this RCT the clinical event rates of the Orsiro SES with a biodegradable polymer the clinical event rates were low and comparable to the Xience PrimeÔ through 12 months in all three analyzed populations.
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Atherosclerotic Background: Bioresorbable polymer coatings are hoped to minimize persistent inflammation associated with durable polymer usage as a drug carrier in drugeluting stents (DES). We examined the time course of para-strut inflammation (PI) of 3 contemporary DES featuring abluminal bioresorbable polymer coating (SYNERGYTM ¼SY) and durable polymer coating (XIENCE PRIME¼EES and RESOLUTE INTEGRITY¼ZES) in the familial hypercholesterolemic swine (FHS) model. Methods: Stents (SE¼29, EES ¼29, ZES¼29 and OMEGA BMS¼29) were implanted in 87 coronary arteries in 29 FHS. Para-strut inflammation (PI) was defined as contiguous regions of inflammation in contact with, or surrounding struts, and extending into the neointima, media or adventitia and examined histologically at 30, 90 and 180 days. Results: At 30 days, PI was higher in BMS compared to the 3 DES. By 90 days, PI had markedly subsided in the BMS, but peaked in all 3 DES groups. At 180 days, PI in the SY resolved to a minimal level comparable to BMS (p¼0.95), while the other 2 DES continued to show higher average PI scores than SY and BMS (EES vs. SY p< 0.0001 and ZES vs. SY p¼0.03). Conclusions: In the setting of early atherosclerosis present in the FHS model at the age used (12-25 months at implant), the peak PI in DES is delayed in comparison to BMS and its resolution is slower. Polymer resorption and lower total mass of the abluminally applied polymer coating in SY appear to accelerate the resolution of PI as projected, adding to the evidence that FHS is capable of modeling clinically relevant responses to endovascular interventions. 
